212 related articles for article (PubMed ID: 30077775)
41. A Microplate-Based Approach to Map Interactions between TDP-43 and α-Synuclein.
Jamerlan AM; An SSA
J Clin Med; 2022 Jan; 11(3):. PubMed ID: 35160025
[TBL] [Abstract][Full Text] [Related]
42. [Proteins and mutations: a new vision (molecular) of neurodegenerative diseases].
Christen Y
J Soc Biol; 2002; 196(1):85-94. PubMed ID: 12134639
[TBL] [Abstract][Full Text] [Related]
43. Inducible Expression of a Truncated Form of Tau in Oligodendrocytes Elicits Gait Abnormalities and a Decrease in Myelin: Implications for Selective CNS Degenerative Diseases.
LoPresti P
Neurochem Res; 2015 Nov; 40(11):2188-99. PubMed ID: 26394614
[TBL] [Abstract][Full Text] [Related]
44. [RNA processing TDP-43 protein has a main pathological role in FTLD and ALS].
Koza P
Postepy Biochem; 2015; 61(2):159-67. PubMed ID: 26689008
[TBL] [Abstract][Full Text] [Related]
45. [Seed, aggregation and propagation of abnormal proteins could explain neurodegeneration?].
Murayama S
Rinsho Shinkeigaku; 2011 Nov; 51(11):1097-9. PubMed ID: 22277493
[TBL] [Abstract][Full Text] [Related]
46. TAR DNA-binding protein 43 in neurodegenerative disease.
Chen-Plotkin AS; Lee VM; Trojanowski JQ
Nat Rev Neurol; 2010 Apr; 6(4):211-20. PubMed ID: 20234357
[TBL] [Abstract][Full Text] [Related]
47. Glial and neuronal tau pathology in tauopathies: characterization of disease-specific phenotypes and tau pathology progression.
Ferrer I; López-González I; Carmona M; Arregui L; Dalfó E; Torrejón-Escribano B; Diehl R; Kovacs GG
J Neuropathol Exp Neurol; 2014 Jan; 73(1):81-97. PubMed ID: 24335532
[TBL] [Abstract][Full Text] [Related]
48. Pathological hallmarks of amyotrophic lateral sclerosis/frontotemporal lobar degeneration in transgenic mice produced with TDP-43 genomic fragments.
Swarup V; Phaneuf D; Bareil C; Robertson J; Rouleau GA; Kriz J; Julien JP
Brain; 2011 Sep; 134(Pt 9):2610-26. PubMed ID: 21752789
[TBL] [Abstract][Full Text] [Related]
49. Lewy bodies in the amygdala: increase of alpha-synuclein aggregates in neurodegenerative diseases with tau-based inclusions.
Popescu A; Lippa CF; Lee VM; Trojanowski JQ
Arch Neurol; 2004 Dec; 61(12):1915-9. PubMed ID: 15596612
[TBL] [Abstract][Full Text] [Related]
50. Pathological properties of the Parkinson's disease-associated protein DJ-1 in alpha-synucleinopathies and tauopathies: relevance for multiple system atrophy and Pick's disease.
Neumann M; Müller V; Görner K; Kretzschmar HA; Haass C; Kahle PJ
Acta Neuropathol; 2004 Jun; 107(6):489-96. PubMed ID: 14991385
[TBL] [Abstract][Full Text] [Related]
51. Therapeutic effect of berberine on TDP-43-related pathogenesis in FTLD and ALS.
Chang CF; Lee YC; Lee KH; Lin HC; Chen CL; Shen CJ; Huang CC
J Biomed Sci; 2016 Oct; 23(1):72. PubMed ID: 27769241
[TBL] [Abstract][Full Text] [Related]
52. Filamentous tau in oligodendrocytes and astrocytes of transgenic mice expressing the human tau isoform with the P301L mutation.
Lin WL; Lewis J; Yen SH; Hutton M; Dickson DW
Am J Pathol; 2003 Jan; 162(1):213-8. PubMed ID: 12507904
[TBL] [Abstract][Full Text] [Related]
53. The role of glia in protein aggregation.
Li Q; Haney MS
Neurobiol Dis; 2020 Sep; 143():105015. PubMed ID: 32663608
[TBL] [Abstract][Full Text] [Related]
54. Multiple system aging-related tau astrogliopathy with complex proteinopathy in an oligosymptomatic octogenarian.
Klotz S; Fischer P; Hinterberger M; Ricken G; Hönigschnabl S; Gelpi E; Kovacs GG
Neuropathology; 2021 Feb; 41(1):72-83. PubMed ID: 33263220
[TBL] [Abstract][Full Text] [Related]
55. The role of oligodendrocytes in chronic pain: cellular and molecular mechanisms.
Malta I; Moraes T; Rodrigues G; Franco P; Galdino G
J Physiol Pharmacol; 2019 Oct; 70(5):. PubMed ID: 31889038
[TBL] [Abstract][Full Text] [Related]
56. Protein targets of oxidative damage in human neurodegenerative diseases with abnormal protein aggregates.
Martínez A; Portero-Otin M; Pamplona R; Ferrer I
Brain Pathol; 2010 Mar; 20(2):281-97. PubMed ID: 19725834
[TBL] [Abstract][Full Text] [Related]
57. The Antiaggregative and Antiamyloidogenic Properties of Nanoparticles: A Promising Tool for the Treatment and Diagnostics of Neurodegenerative Diseases.
Pichla M; Bartosz G; Sadowska-Bartosz I
Oxid Med Cell Longev; 2020; 2020():3534570. PubMed ID: 33123310
[TBL] [Abstract][Full Text] [Related]
58. Understanding Amyloid Structures and Disease: A Continuing Challenge in Health Research.
Chiellini G
Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34205606
[TBL] [Abstract][Full Text] [Related]
59. Pathology of Neurodegenerative Diseases.
Dugger BN; Dickson DW
Cold Spring Harb Perspect Biol; 2017 Jul; 9(7):. PubMed ID: 28062563
[TBL] [Abstract][Full Text] [Related]
60. Functions and dysfunctions of oligodendrocytes in neurodegenerative diseases.
Han S; Gim Y; Jang EH; Hur EM
Front Cell Neurosci; 2022; 16():1083159. PubMed ID: 36605616
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
